成人重性抑郁障碍维持期抗抑郁药治疗:系统综述与网络meta分析
该研究纳入34项双盲随机安慰剂对照富集设计试验(n=9384,平均年龄43.80岁,女性68.10%),比较20种抗抑郁药治疗成人MDD维持期的疗效、可接受性、耐受性和安全性;结果显示去甲文拉法辛、帕罗西汀、文拉法辛和伏硫西汀兼具合理的疗效、可接受性和耐受性。
要点
- 去甲文拉法辛、帕罗西汀、文拉法辛和伏硫西汀在维持期兼具合理疗效与可接受性。
- 舍曲林因不良事件停药率高于安慰剂,去甲文拉法辛、舍曲林和伏硫西汀恶心/呕吐发生率更高。
核心结论
- 去甲文拉法辛、帕罗西汀、文拉法辛和伏硫西汀在成人稳定期MDD维持治疗中具有合理的疗效、可接受性和耐受性。
研究设计与样本
- 系统综述与随机效应模型网络meta分析,仅纳入双盲、随机、安慰剂对照的富集设计试验:开放标签期先用目标抗抑郁药稳定病情,再随机接受同种抗抑郁药或安慰剂。
- 检索PubMed、Cochrane Library和Embase数据库,共纳入34项研究(n=9384,平均年龄43.80岁,女性68.10%),涉及20种抗抑郁药和安慰剂。
主要发现
- 在6个月复发率方面,阿米替林、西酞普兰、去甲文拉法辛、度洛西汀、氟西汀、氟伏沙明、米氮平、奈法唑酮、帕罗西汀、瑞波西汀、舍曲林、噻奈普汀、文拉法辛和伏硫西汀优于安慰剂。
- 与安慰剂相比,去甲文拉法辛、帕罗西汀、舍曲林、文拉法辛和伏硫西汀的全因停药率更低。
- 与安慰剂相比,文拉法辛的头晕发生率更低,而去甲文拉法辛、舍曲林和伏硫西汀的恶心/呕吐发生率更高。
- 与安慰剂相比,舍曲林因不良事件停药率更高。
关键数值与推荐
- 主要结局为6个月复发率,效应量为风险比(95%可信区间)。
- 可接受性采用全因停药率评估,耐受性采用因不良事件停药率评估,安全性采用个体不良事件发生率评估。
临床怎么用
- 对于已用目标抗抑郁药稳定病情的成人MDD患者,维持期可优先考虑去甲文拉法辛、帕罗西汀、文拉法辛或伏硫西汀以兼顾疗效与耐受性。
- 选用舍曲林维持治疗时需关注因不良事件停药风险;使用去甲文拉法辛、舍曲林或伏硫西汀时需监测恶心/呕吐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A systematic review and random-effects model network meta-analysis were conducted to compare the efficacy, acceptability, tolerability, and safety of antidepressants to treat adults with major depressive disorder (MDD) in the maintenance phase. This study searched the PubMed, Cochrane Library, and Embase databases and included only double-blind, randomized, placebo-controlled trials with an enrichment design: patients were stabilized on the antidepressant of interest during the open-label study and then randomized to receive the same antidepressant or placebo. The outcomes were the 6-month relapse rate (primary outcome, efficacy), all-cause discontinuation (acceptability), discontinuation due to adverse events (tolerability), and the incidence of individual adverse events. The risk ratio with a 95% credible interval was calculated. The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, amitriptyline, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, tianeptine, venlafaxine, vilazodone, and vortioxetine) and a placebo. In terms of the 6-month relapse rate, amitriptyline, citalopram, desvenlafaxine, duloxetine, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, tianeptine, venlafaxine, and vortioxetine outperformed placebo. Compared to placebo, desvenlafaxine, paroxetine, sertraline, venlafaxine, and vortioxetine had lower all-cause discontinuation; however, sertraline had a higher discontinuation rate due to adverse events. Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had reasonable efficacy, acceptability, and tolerability in the treatment of adults with stable MDD.
引用
- Kishi T, Ikuta T, Sakuma K, et al. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2022. PMID: 36253442. doi:10.1038/s41380-022-01824-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。